Related Experiment Video
Updated: Jun 10, 2025
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Melatonin Inhibits ET-1 Production to Break Crosstalk Between Prostate Cancer and Bone Cells: Implication for
Liang-Wei Lin1, Tien-Huang Lin2,3, Sanskruti Swain1
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Abstract:
Bone metastasis is the primary cause of death among patients with advanced prostate cancer (PCa). PCa tends to spread to bones and acquire the bone-like phenotype, causing osteoblastic bone metastasis. Unfortunately, there is no effective treatment for this condition. However, melatonin, which regulates our circadian rhythm, has been found to have anti-tumor properties. It has yet to be established whether it is effective in treating osteoblastic PCa metastasis. Our findings show that melatonin inhibits the production of endothelin-1 (ET-1) in osteoblastic PCa cells, suppressing osteoblast differentiation. Clinical results indicate that bone metastatic PCa patients have higher levels of ET-1 compared to nonmetastatic PCa patients. Furthermore, melatonin-induced miR-let-7f-5p inhibits ET-1-promoted osteoblast differentiation in osteoblastic PCa. Melatonin also suppresses the property of osteomimicry in osteoblastic PCa cells. Importantly, in the intratibia injection PCa metastasis model, melatonin decreased osteoblastic PCa tumor growth, inhibiting ET-1 production and osteoblast differentiation in vivo. Taken together, melatonin inhibits osteoblastic PCa-regulated osteoblastogenesis by reducing ET-1 production through upregulation of miR-let-7f-5p, while suppressing the property of osteomimicry in osteoblastic PCa. Melatonin therapy could be a promising approach to treating bone metastasis in osteoblastic PCa.
Insights
Melatonin shows promise for treating prostate cancer (PCa) bone metastasis. It inhibits tumor growth by reducing endothelin-1 (ET-1) and osteoblast differentiation, offering a potential new therapy.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Bone metastasis is a major cause of mortality in advanced prostate cancer (PCa).
- Osteoblastic bone metastasis in PCa lacks effective treatments.
- Melatonin, a circadian rhythm regulator, exhibits anti-tumor properties.
Purpose of the Study:
- To investigate melatonin's efficacy in treating osteoblastic PCa bone metastasis.
- To elucidate the molecular mechanisms underlying melatonin's anti-metastatic effects.
Main Methods:
- In vitro studies on osteoblastic PCa cells.
- Analysis of endothelin-1 (ET-1) and miR-let-7f-5p levels.
- In vivo intratibia injection PCa metastasis model.
Main Results:
- Melatonin suppressed endothelin-1 (ET-1) production and osteoblast differentiation in PCa cells.
- Elevated ET-1 levels were observed in bone metastatic PCa patients.
- Melatonin-induced miR-let-7f-5p inhibited ET-1-promoted osteoblastogenesis.
- Melatonin reduced osteoblastic PCa tumor growth in vivo.
Conclusions:
- Melatonin inhibits osteoblastic PCa bone metastasis by reducing ET-1 production via miR-let-7f-5p upregulation.
- Melatonin therapy is a potential strategy for treating osteoblastic PCa bone metastasis.
